Topics

Tumor Angiogenesis Regulates Tumor Immune Response

Tumor Microenvironment Cancer Immunotherapy Intercellular Communication & Diseases Cellular Stress

Tumor angiogenesis regulates immunity because blood vessels control oxygen, nutrients, immune-cell entry, and the movement of therapeutic agents. VEGF-driven vessels are often tortuous, leaky, poorly perfused, and functionally hostile to lymphocyte adhesion. VEGF also acts directly and indirectly on dendritic cells, T cells, regulatory T cells, and suppressive myeloid populations. This creates a reciprocal cycle: angiogenesis supports an immunosuppressive tumor microenvironment, and immune suppression permits continued vascular abnormality. The recognition of this cycle provided the rationale for combining antiangiogenic therapy with immune checkpoint blockade. The goal is not simply to remove vessels, but to transiently normalize perfusion and endothelial function so that antitumor immunity can enter and operate Endothelial cells are therefore active participants in immune selection, not passive tubes that merely supply a growing mass with oxygen and nutrients[1][2][3].

VEGF signaling through VEGF receptors promotes endothelial growth and abnormal vascular permeability. Hypoxia resulting from poor perfusion stabilizes programs that increase VEGF, recruit myeloid-derived suppressor cells, favor regulatory T cells, and impair effector-cell metabolism. Endothelial cells can reduce adhesion molecules needed for lymphocyte extravasation and create a selective barrier to tumor-reactive cells. VEGF can hinder dendritic-cell maturation and reinforce checkpoint expression. Antiangiogenic treatment at an appropriate intensity may improve perfusion, reduce hypoxia, restore leukocyte trafficking, and shift myeloid composition. Excessive vessel pruning can have the opposite effect by deepening hypoxia and limiting drug or immune-cell delivery The concept of a normalization window explains why dose escalation can be counterproductive even when it produces stronger biochemical inhibition of VEGF signaling[1][2][3].

Clinical applications include combinations of VEGF- or VEGFR-directed agents with PD-1 or PD-L1 inhibitors in several solid tumors. These regimens can address two resistance layers simultaneously: vascular exclusion and T-cell inhibition. Biomarkers remain imperfect because vessel density alone does not measure normalization. Blood pressure, proteinuria, bleeding, thrombosis, wound-healing complications, and immune-related adverse events require integrated management. Timing around surgery is particularly important. Other strategies target ANGPT2, endothelial checkpoints, or vessel-associated stromal pathways. Radiation and cellular therapy may also benefit from improved perfusion, but combinations should verify that vascular modulation increases intratumoral immune access rather than merely changing imaging These combinations already demonstrate that vascular and immune therapies can cooperate clinically, while variable response shows that VEGF dependence is not universal[1][2].

Research needs dynamic measurements of perfusion, hypoxia, endothelial activation, and immune trafficking. Paired biopsies and functional imaging can identify the normalization window and guide the dose and sequence of checkpoint therapy. Spatial analyses should distinguish immune cells trapped around vessels from those entering tumor nests. Resistance may arise through alternative angiogenic factors, vessel co-option, or myeloid adaptation, requiring mechanism-specific combinations. Trials should also separate effects on tumor growth from immune-mediated effects. Tumor vasculature is both infrastructure and an immune regulator; durable therapeutic benefit will require maintaining enough functional circulation for immune access while suppressing the signaling that makes those vessels abnormal and immunologically restrictive Validated biomarkers could prevent prolonged exposure when a tumor uses vessel co-option or an alternative angiogenic program that the selected agent does not block. Normal-tissue vascular recovery should be monitored after prolonged combination treatment[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family   Ephrin Receptor   PDGFR  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
316
HY-10231 PX-478
PX-478 is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis.
HIF/HIF Prolyl-Hydroxylase   VEGFR   Autophagy  
Blood Disease   Type 1 Diabetes   Atherosclerosis  
115
HY-10255A Sunitinib
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
VEGFR   PDGFR   IRE1   Mitophagy   Autophagy   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Lung Fibrosis  
113
HY-10981 Lenvatinib
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
VEGFR   FGFR   PDGFR   c-Kit   RET  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   SARS-CoV-2 Infection   Lung Fibrosis  
104
HY-10331A Regorafenib monohydrate
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity.
VEGFR   Autophagy   PDGFR   Raf   RET   FGFR   c-Kit   Tie  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
96
HY-10331 Regorafenib
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity.
VEGFR   Autophagy   PDGFR   Raf   RET   c-Kit   FGFR   Tie  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
96
HY-L015 PI3K/Akt/mTOR Compound Library
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 1,149 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Signaling Pathway Targeting Libraries

90
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L045 Oxygen Sensing Compound Library
Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival. HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O2 concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation. MCE offers a unique collection of 4,317 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Signaling Pathway Targeting Libraries

83
HY-L088 Angiogenesis-Related Compound Library
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer). MCE offers a unique collection of 3,660 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Signaling Pathway Targeting Libraries

83
HY-L103 Anti-Colorectal Cancer Compound Library
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,653 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L125 Anti-Pulmonary Fibrosis Compound Library
Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 2,810 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

Disease Focused Libraries

83
HY-L132 Chemokine Compound Library
Chemokines, or chemotactic cytokines, are small cytokines or signaling proteins secreted by cells. They are a component of intercellular communication, controlling the directional movement of immune cells especially leukocytes, as well as other cell types, for instance, endothelial and epithelial cells, which are essential to maintain human health and the function of the immune system. The biological effects of chemokines are achieved by binding to chemokine receptors, which are G protein-coupled receptors found on the surface of leukocytes. Some chemokine receptors are involved in directing tumor metastasis and over-expression by certain tumors. So inhibiting the interaction between chemokine and chemokine receptors on the surface of tumor cells may be a new possible therapeutic approach. Some chemokine receptors are coreceptors for HIV entry, and related inhibitors have been approved by the FDA to treat patients with HIV. Obviously, chemokines and chemokine receptors have become new targets for studying cancer, HIV, inflammation, and other diseases. MCE supplies a unique collection of 257 chemokine or chemokine receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on chemokine or chemokine receptors. MCE Chemokine Library is a useful tool for drug research related to cancer, AIDS, and wound therapy.

Signaling Pathway Targeting Libraries

83
HY-L172 Immunopotentiator Compound Library
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines. MCE designs a unique collection of 150 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

Compound Characteristic Classified Libraries

83
HY-L174 Macrophage Related Compound Library
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Compound Characteristic Classified Libraries

83
HY-L204 Lactic Acid Metabolic Compound Library
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism. MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L227 Amino Acid Metabolite Compound Library
Amino acids are the fundamental components that sustain life activities, playing roles in ATP generation, promoting nucleotide synthesis, and maintaining cellular redox balance. Moreover, dysregulation of amino acid consumption is a significant potential regulatory mechanism leading to impaired anti-tumor immunity in immune cells. The normal functioning of immune cells relies on amino acid metabolic pathways to obtain energy and materials, and upon activation, they reprogram their metabolism to support growth, proliferation, and effector functions. Additionally, metabolic disorders of specific amino acids (such as branched-chain amino acids, glutamine, and arginine) can exacerbate mitochondrial dysfunction and oxidative stress, thereby promoting myocardial fibrosis and cardiac cell damage. Therefore, conducting research related to amino acid metabolism holds promise for discovering potential drugs for diseases related to cancer, immunity, and metabolism. MCE can provide 195 kinds of metabolites of amino acid metabolic pathways, which can be used for drug screening in various diseases such as cancer, immune disorders, metabolic diseases, mitochondrial-targeted diseases

Metabolism Focused Libraries

83
HY-L234 Nucleotide Metabolite Compound Library
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs. MCE can provide 83 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

Metabolism Focused Libraries

83
HY-L250 Lactic Acid Metabolite Compound Library
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies. The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.

Signaling Pathway Targeting Libraries

83
HY-L253 Fungal-Sourced Compound Library
For thousands of years, natural products have always been an important source for drug discovery. Fungi, due to their unique and diverse secondary metabolic capabilities, have become a valuable resource for natural active molecules. Since the discovery of penicillin, natural products derived from fungi have demonstrated significant application value in areas such as anti-infection, anti-tumor, immune regulation, and metabolic disease research. A large number of clinical drugs, such as antibiotics, immunosuppressants, and lipid-lowering drugs, are derived from fungal metabolites or their structurally optimized derivatives. MCE fungal-derived compound library contains 91 structurally diverse and bioactive fungal natural products and their derivatives. It can be widely applied in various research fields such as antibacterial, anti-tumor, anti-inflammatory, immune regulation, epigenetics, and cell signaling pathways, providing high-quality tools for natural product drug development and high-throughput screening.

Natural Product Screening Libraries

83
HY-L919 MCE CNS BBB Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

Focused and target libraries

83
HY-10374 Semaxinib
Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC50 of 1.23 μM.
VEGFR  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   HIV Infection   Non-Small Cell Lung Cancer   Lung Fibrosis  
81
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-50904 Nintedanib
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
PDGFR   VEGFR   FGFR  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Lung Fibrosis  
75
HY-B2227 Lactic acid
Lactic acid (DL-Lactic acid) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid also has antimicrobial activity, which can be used as a food preservative.
Environmental Pollutants   Hydroxycarboxylic Acid Receptor (HCAR)   Bacterial   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
67
HY-P9906 Bevacizumab
Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer.

Species: Human

VEGFR  
Inflammation or Immune System Disease   Cardiovascular Disease   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer  
63
HY-13016 Cabozantinib
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
VEGFR   c-Met/HGFR   c-Kit   TAM Receptor   FLT3   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Digestive System Inflammation   Lung Fibrosis  
59
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-K6002 Basement Membrane Matrix

MCE Basement Membrane Matrix is primarily composed of natural basement membrane matrix extracted from mouse tumors.This product is mainly used for studies of tumor invasion, angiogenesis and organoids culture while avoiding color interference in subsequent experiments.

Cell Biology 3D Cell Culture Basement Membrane Matrix

25
HY-N0183 Formononetin
Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.
FGFR   Apoptosis  
Lung Cancer   Prostate Cancer   Liver Cancer   Digestive System Inflammation   Cardiovascular Disease   Obesity  
24
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-B0633A Hyaluronic acid
Hyaluronic acid is a biopolymer composed of repeating units of disaccharides with various applications. Hyaluronic acid is a major component of the extracellular matrix (ECM). Hyaluronic acid is synthesized at the plasma membrane. Increased hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion and angiogenesis in digestive cancers. Hyaluronic acid participates in tissue remodeling and rapid cell proliferation in some physiological processes including embryonic morphogenesis and wound-healing. Hyaluronic acid activates the PI3K-Akt signaling. Hyaluronic acid acts as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting proteolytic MMP-9 binding to cell surface or stimulating MMP-9 binding to cell surface. Hyaluronic acid can be used as drug delivery for sodium butyrate to improve the anti-proliferative activity on breast cancer cell line. Hyaluronic acid can be studied in joint diseases, wound healing and cancer.
Endogenous Metabolite   Bacterial   Akt   PI3K  
Breast Cancer   Prostate Cancer   Pancreatic Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   SARS-CoV-2 Infection  
21
HY-K6001 Basement Membrane Matrix (Phenol Red)

MCE Basement Membrane Matrix (Phenol Red) is primarily composed of a natural basement membrane matrix derived from mouse tumors. This product is mainly for studies of tumor invasion, angiogenesis, and organoid culture.

Cell Biology 3D Cell Culture Basement Membrane Matrix

21
HY-B2227D Calcium 2-hydroxypropanoate pentahydrate
Calcium 2-hydroxypropanoate (pentahydrate) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Calcium 2-hydroxypropanoate (pentahydrate) is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Calcium 2-hydroxypropanoate (pentahydrate) is an oncometabolite and has immune protective role of lactate in anti-tumor immunity.
Environmental Pollutants   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
20
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-Y0966 Glycine
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis.
Ninjurin   Endogenous Metabolite   VEGFR   PROTAC Linkers   iGluR  
Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Schizophrenia   Pain   Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Multiple Myeloma   HSV Infection   SARS-CoV-2 Infection   Alzheimer's Disease   Lung Fibrosis  
18
HY-N0784 Ginkgolide B
Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.
Platelet-activating Factor Receptor (PAFR)   Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease  
13
HY-13024 Rebastinib
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC50 values of 0.8 nM and 4 nM against Abl1WT and Abl1T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC50 = 0.0533 μM) and CYP2C9 (IC50 = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC50 of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia.
Bcr-Abl   Cytochrome P450   Tie   FOXO   Src   FLT3   Apoptosis  
Pancreatic Cancer   Triple-Negative Breast Cancer   Muscular Dystrophy  
13
HY-N0517 Erianin
Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis.
Bacterial  
Cancer   Neurological, Eye or Ear Disease   Bacterial Infection   Obesity  
12
HY-113046 5-Methyltetrahydrofolic acid
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases.
Endogenous Metabolite  
Metabolic or Endocrine Disease   Cardiovascular Disease  
12
HY-N7073 Silymarin
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (Mpro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research.
SARS-CoV  
Neurological, Eye or Ear Disease   Liver Cancer   Viral Infection   Digestive System Inflammation   Obesity  
11
HY-N6653 Lentinan
Lentinan is an orally active biocompatible multifunctional polysaccharide with biological activities such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, hypoglycemic, and lipid-lowering.
JAK   Keap1-Nrf2   Apoptosis  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
9
HY-110066 (Z)-Guggulsterone
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis. (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection.
Apoptosis   VEGFR   Akt   Angiotensin-converting Enzyme (ACE)   SARS-CoV   FXR  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Pain   Digestive System Inflammation   Hypertension   Obesity   Lung Fibrosis  
8
HY-K3002 DMEM/F-12 (1:1), L-Glutamine, Phenol Red, HEPES

DMEM/F-12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12) is a widely used basal medium for supporting the growth of many different mammalian cells. Cell successfully cultured in DMEM/F-12 include MDCK, glial cells, fibroblasts, human endothelial cells, etc. The 500 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

Cell Biology Cell Culture Basal Cell Culture Media

8
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-N0587 Demethylzeylasteral
Demethylzeylasteral is an orally active triterpenoid compound isolated from Tripterygium wilfordii, which has functions such as anti-inflammatory, anti-tumor, anti fertility, estrogen metabolism regulation, immune suppression, and immune system regulation .
Apoptosis   TGF-beta/Smad   Estrogen Receptor/ERR   NF-κB   FAK  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Triple-Negative Breast Cancer   Obesity   Lung Fibrosis  
6
HY-P80929 VEGFA Antibody (YA013)
VEGFA Antibody (YA013) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGFA.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

6
HY-P1408 Obtustatin
Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma.
Integrin   VEGFR  
Lung Cancer  
4
HY-P0073 Tyr-Gly-Gly-Phe-Met-OH
Tyr-Gly-Gly-Phe-Met-OH regulates human immune function and inhibits tumor growth via binding to the opioid receptor.
Opioid Receptor  
Cancer   Depression   Pain  
4
HY-109041 Razuprotafib
Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC50of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC50 of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC50=36 pM) and HPTPγ (100 pM).
Phosphatase   Tie  
Inflammation or Immune System Disease  
4
HY-P99041B Panitumumab (powder)
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer.

Species: Human

EGFR  
Cancer  
2
HY-111334 Brassinin
Brassinin is an indole derivative found in cruciferous plants. Brassinin acts as an IDO inhibitor (Ki = 97.7 μM). Brassinin inhibits angiogenesis and induces apoptosis, autophagy, paraptosis, ROS production, and ER stress. Brassinin selectively stimulates lysosomal degradation of Tie2 and promotes lysosomal and proteasomal degradation of FGFR1 in endothelial cells, downregulating AKT and ERK phosphorylation. Brassinin inhibits endothelial cell proliferation, migration, tube formation, spheroid sprouting, and angiogenesis. Brassinin inhibits PI3K/Akt/mTOR/S6K1 signaling, upregulates p21 and p27, and induces G1 phase cell cycle arrest through RB hypophosphorylation. Brassinin inhibits tyrosinase catalytic activity, reduces tyrosinase mRNA, and inhibits MITF nuclear translocation. Brassinin is used for research on triple-negative breast cancer, chronic myeloid leukemia, colon cancer, glioma, atherosclerosis, and skin cancer.
Endogenous Metabolite   Indoleamine 2,3-Dioxygenase (IDO)   Apoptosis   Autophagy   Paraptosis   Reactive Oxygen Species (ROS)   Tie   Akt   PERK   PI3K   mTOR   Ribosomal S6 Kinase (RSK)  
Colorectal Cancer   Glioma   Skin Disease   Triple-Negative Breast Cancer   Chronic Myelogenous Leukemia   Atherosclerosis  
2
HY-N0249 Saikosaponin C
Saikosaponin C is an orally active MMP-2 inducer. Saikosaponin C induces the survival, growth, migration and capillary tube formation of endothelial cells. Saikosaponin C inhibits the early stage of hepatitis C virus infection. Saikosaponin C can be used in research related to ischemic tissue diseases, chronic kidney diseases and hepatitis C virus infection.
MMP  
Hepatitis C Virus Infection   Chronic Kidney Disease  
2
HY-N0724 Mesaconitine
Mesaconitine is a nitric oxide synthase activator. Mesaconitine drives extracellular Na+ and Ca2+ influx into endothelial cells, increases intracellular Na+ and Ca2+ concentrations, and triggers nitric oxide release. Mesaconitine is applicable for pain-related research.
NO Synthase  
Pain  
2
HY-107818 4-Hydroxychalcone
4-Hydroxychalcone is an orally active flavonoid precursor. 4-Hydroxychalcone inhibits VEGF- and bFGF-induced phosphorylation of ERK1/2 and Akt. 4-Hydroxychalcone suppresses resistant hypertension by alleviating hyperaldosteronism, inflammation and renal injury in cryptochrome gene knockout mice. 4-Hydroxychalcone possesses anti-angiogenic activity.
ERK   Akt  
Inflammation or Immune System Disease   Renal Disease   hCoV-OC43   Hypertension   Atrial Fibrillation  
2
HY-16782 Pexmetinib
Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis.
Tie   p38 MAPK   STAT   Nuclear Factor of activated T Cells (NFAT)   MMP   TNF Receptor  
Musculoskeletal and Skin Disease   Breast Cancer   Acute Myeloid Leukemia  
2
HY-P99051 Tinurilimab
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
2
HY-108801A Aflibercept (VEGF Trap)
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.

Species: Human

VEGFR  
Colorectal Cancer   Hypertension  
2
HY-108801 Aflibercept
Aflibercept is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.

Species: Human

VEGFR  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease   Non-Small Cell Lung Cancer  
2
HY-P9951A Ranibizumab (anti-VEGF)
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research.

Species: Human

VEGFR  
Blood or Cardio-cerebrovascular Disease  
2
HY-N9470 λ-Carrageenan
λ-Carrageenan is a seaweed polysaccharide which has been generally used as proinflammatory agent in the basic research. λ-Carrageenan is a potent antitumor agent.
Others  
Inflammation or Immune System Disease  
2
HY-W145521 β-1,3-Glucan
β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to Vibrio harveyi infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors.
Biochemical Assay Reagents   IKK   NO Synthase   Bacterial  
Cancer   Infection   Inflammation or Immune System Disease  
2
HY-125864 Fibrinogen (Bovine)
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases.
Interleukin Related   NF-κB  
Inflammation or Immune System Disease  
2
HY-P99041 Panitumumab
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer.

Species: Human

EGFR  
Bladder Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer  
2
HY-NP181 Testosterone/BSA
Testosterone/BSA, a conjugate of Testosterone (HY-113415) and bovine serum albumin (BSA), acts as a nuclear transporter and cytoplasmic accumulator. Testosterone/BSA can enter the nuclei of rat testicular spermatocytes, spermatids and rat liver endothelial cells, while the antigenicity of BSA remains intact. Testosterone/BSA accumulates in the cytoplasm of rat hepatocytes in granular form. Testosterone/BSA can be used to investigate the membrane-initiated or non-genomic activities of steroid hormones.
Biochemical Assay Reagents  
1
HY-P99905 Efdamrofusp alfa
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.
VEGFR  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
1
HY-18963 Lavendustin A
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis.

Source: Streptomyces griseolavendus

EGFR  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Hepatitis C Virus Infection   Obesity  
1
HY-P1663 ATWLPPR Peptide
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)
VEGFR  
1
HY-P99732 Minretumomab
Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research.

Species: Human

Mucin  
Cancer  
1
HY-B0708 β-Estradiol 17-acetate
β-Estradiol 17-acetate (1,3,5(10)-Estratriene-3,17β-diol 17-acetate) is a long-acting endogenous estrogen precursor and also a cell viability and proliferation enhancer. β-Estradiol 17-acetate promotes the adhesion and proliferation of freshly isolated and revived female-derived human brain microvascular endothelial cells, and reverses the decreased viability of revived male-derived human brain microvascular endothelial cells. β-Estradiol 17-acetate exerts the microvascular protective effect of estrogen, enabling non-tumor human brain microvascular endothelial cells to be cultured in vitro for 2 months after cryopreservation. β-Estradiol 17-acetate is biotransformed into β-estradiol via hydrolase action in the in vitro skin of humans, hairless dogs, rats and hairless mice.

Source: the skin of various animal models

Estrogen Receptor/ERR  
Gonadal Disease  
1
HY-126437 Poly-L-lysine hydrobromide (MW 30000-70000)
Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and p53 proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material.
Apoptosis   Bcl-2 Family   MDM-2/p53   VEGFR  
Blood or Cardio-cerebrovascular Disease  
1
HY-P0132 YIGSR
YIGSR (Laminin Fragment 929-933) is a polypeptide that inhibits tumor growth and metastasis of leukemia cells. YIGSR specifically binds to the 67kDa laminin receptor and regulates the expression of eNOS in endothelial cells. YIGSR can be used in leukemia-related research.
NO Synthase  
Cancer  
1
HY-P5133 Synstatin (92-119)
Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma.
Integrin  
Cancer  
1
HY-N5112B β,β-Dimethylacrylshikonin
β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative that can be isolated from Lithospermum erythrorhizon Sieb. et Zucc. β,β-Dimethylacrylshikonin promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. β,β-Dimethylacrylshikonin inhibits Notch-1 activation. β,β-Dimethylacrylshikonin inhibtis tumor cell proliferation, induces tumor cell apoptosis, and inhibits tumor growth.
HIF/HIF Prolyl-Hydroxylase   Apoptosis   Notch   NO Synthase   Bcl-2 Family  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Digestive System Inflammation   Rheumatoid Arthritis  
1
HY-100756 BAY-826
BAY-826, a chemical probe, is a selective and potent TIE-2 inhibitor with a Kd of 1.6 nM, respectively.
Discoidin Domain Receptor   Tie  
Cancer  
1
HY-Y0892 4-Hydroxybenzyl alcohol
4-Hydroxybenzyl alcohol is a phenolic compound widely distributed in various kinds of plants. Anti-inflammatory, anti-oxidant, anti-nociceptive activity. Neuroprotective effect. Inhibitor of tumor angiogenesis and growth.
Apoptosis   Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation   Obesity  
1
HY-100556 Tie2 kinase inhibitor 1
Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM. Tie2 kinase inhibitor 1 has anti-cancer activity.
Tie  
Cancer  
1
HY-P990148 Anti-Mouse VEGF-A Antibody (2G11-2A05)
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a κ type antibody inhibitor, tragrting to mouse VEGF-A with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models.

Species: Mouse

VEGFR  
Gastric Cancer  
1
HY-W009749 L-Cystathionine
L-Cystathionine is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs). L-Cystathionine plays an important role in cardiovascular protection.
Endogenous Metabolite   Apoptosis  
Blood or Cardio-cerebrovascular Disease  
1
HY-170230 Bovine Endothelial cell growth supplement,suitable for cell culture
Bovine Endothelial cell growth supplement, suitable for cell culture (ECGS, Bovine) is a culture medium supplement, endothelial cell growth supplement (ECGS), which promotes the proliferation of human saphenous vein endothelial cells (HSVEC) and human umbilical vein endothelial cells (HUVEC).
Biochemical Assay Reagents  
1
HY-P9920A Ramucirumab (anti-VEGFR)
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor.

Species: Human

VEGFR  
Cancer  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P7110 VEGF165 Protein, Human (P.pastoris)
VEGF165 Protein, Human (P.pastoris) is a Vascular Endothelial Growth Factor A (VEGF-A) isoform. VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis.

Species: Human; Source: P. pastoris

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

1
HY-K6005 Basement Membrane Matrix HC (Phenol Red)

MCE Basement Membrane Matrix HC (High Concentration, Phenol Red) is primarily composed of natural basement membrane matrix extracted from mouse tumorsand contains abundant extracellular matrix components and a variety of naturally occurring growth factors. This product is mainly used for angiogenesis experiments, construction of animal models and 3D tumor models.

Cell Biology 3D Cell Culture Basement Membrane Matrix

1
HY-121356S1 Carebastine-d5 Methyl Ester
Carebastine-d5 Methyl Ester is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner. Carebastine suppresses the expression of macrophage migration inhibitory factor.
Isotope-Labeled Compounds   Histamine Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-121356S Carebastine-d5
Carebastine-d5 is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner. Carebastine suppresses the expression of macrophage migration inhibitory factor.
Isotope-Labeled Compounds   Histamine Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-18963R Lavendustin A (Standard)
Lavendustin A (Standard) is the analytical standard of Lavendustin A. This product is intended for research and analytical applications. Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].
Reference Standards   EGFR  
Cancer  
/
HY-P992422 NG004
NG004 is a fully human monoclonal antibody targeting Nogo-A. NG004 reduces retinal Nogo-A levels, blocks the binding of the Nogo-A-receptor complex, and neutralizes the Nogo-A protein. NG004 can be used in studies related to diabetic retinopathy, stroke and acute spinal cord injury.

Species: Human

Transmembrane Glycoprotein  
Nervous System Injury   Retinopathy  
/
HY-128749AR D-Glucaric acid tetrahydrate (Standard)
D-Glucaric acid tetrahydrate (Standard) (Calcium D-glucarate tetrahydrate (Standard)) is the analytical standard of D-Glucaric acid tetrahydrate (HY-128749A). This product is intended for research and analytical applications. D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases.
Endogenous Metabolite   Reference Standards   Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-D3419 Neuro-DiO 4-chlorobenzenesulfonate
Neuro-DiO 4-chlorobenzenesulfonate is a hydrophobic C18 alkyl chain carbocyanine dye with green fluorescence, commonly used as a vascular marker, cell internalizer and deposition agent. Neuro-DiO 4-chlorobenzenesulfonate inserts its alkyl chain into the endothelial plasma membrane via liposome-mediated perfusion to achieve vascular labeling. Neuro-DiO chlorobenzenesulfonate can also stain the cell membrane and cytoplasm of cancer cells to assist in confocal microscopy observations. Neuro-DiO chlorobenzenesulfonate can be released from nanosponges and accumulate on the surface of mouse retina, then internalize into retinal ganglion cells, which is applicable to researches related to glaucoma and other diseases. It should be noted that during liposome-mediated vascular staining in mice, Neuro-DiO 4-chlorobenzenesulfonate may cause leakage of airway lavage fluid.
Fluorescent Dye  
Glaucoma  
/
HY-P0073S Tyr-Gly-Gly-{Phe-13C9,15N}-Met-OH TFA
Tyr-Gly-Gly-{Phe-13C9,15N}-Met-OH TFA (Met-Enkephalin-13C9,15N TFA) is the 13C- and 15N-labeled Tyr-Gly-Gly-Phe-Met-OH TFA. Tyr-Gly-Gly-Phe-Met-OH regulates human immune function and inhibits tumor growth via binding to the opioid receptor.
Isotope-Labeled Compounds   Opioid Receptor  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P10521 Apolipoprotein KV domain (67-77)
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research.
VEGFR  
/
HY-P992200 Anti-CD146 Antibody (AA98)
Anti-CD146 Antibody (AA98) is an antibody targeting CD146 and an angiogenesis inhibitor. Anti-CD146 Antibody (AA98) blocks the dimerization of CD146 as well as its downstream PI3K/AKT, p38 MAPK and NF-κB signaling pathways; it inhibits the expression of MMP9 and ICAM1, epithelial-mesenchymal transition (EMT), and the proliferation, migration and tube formation of endothelial cells. Anti-CD146 Antibody (AA98) enhances radiation-induced cancer cell apoptosis and survival inhibition, reduces tumor microvessel density, and suppresses tumor growth, invasion and vasculogenic mimicry. Anti-CD146 Antibody (AA98) can be used in research related to cervical cancer, liver cancer, malignant phyllodes tumor of the breast, uveal melanoma, leiomyosarcoma, pancreatic cancer, other tumors and angiogenesis.

Species: Human

Transmembrane Glycoprotein   PI3K   Akt   p38 MAPK   NF-κB   MMP   Apoptosis   Caspase   Bcl-2 Family  
Blood or Cardio-cerebrovascular Disease   Liver Cancer   Cervical Cancer   Pancreatic Cancer   Melanoma  
/
HY-P11062 M30 peptide
M30 peptide is an MHC class II epitope antigen that can be used in cancer nanovaccine research.
Others  
/
HY-P11061 M27 peptide
M27 peptide is an MHC class I epitope antigen that can be used in cancer nanovaccine research.
Others  
/
HY-P0073S1 Tyr-{Gly-13C2,15N}-Gly-Phe-Met-OH TFA
Tyr-{Gly-13C2,15N}-Gly-Phe-Met-OH TFA (Met-Enkephalin-13C2,15N TFA) is the 13C- and 15N-labeled Tyr-Gly-Gly-Phe-Met-OH TFA. Tyr-Gly-Gly-Phe-Met-OH regulates human immune function and inhibits tumor growth via binding to the opioid receptor.
Isotope-Labeled Compounds   Opioid Receptor  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P992082 Anti-Human/Rat VEGF Antibody (A.4.6.1)
Anti-Human/Rat VEGF Antibody (A.4.6.1) is an antibody targeting human and rat vascular endothelial growth factor (VEGF) that potently inhibits tumor growth in various animal models. Anti-Human/Rat VEGF Antibody (A.4.6.1) is the parent antibody of Bevacizumab (HY-P9906), and it exhibits high affinity and high selectivity for binding to human VEGF. The isotype control for Anti-Human/Rat VEGF Antibody (A.4.6.1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Human/Rat

VEGFR  
Cancer  
/
HY-P3999 Fibulostatin 6.2
Fibulostatin 6.2 is an anti-angiogenic peptide that can inhibit migration of human umbilical vein endothelial cells in vitro.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10496 MAGE-A1-derived peptide
MAGE-A1-derived peptide is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide can be used in the study of tumor immunity.
Others  
/
HY-NP090B Ulex Europaeus Agglutinin I-AF350
Ulex Europaeus Agglutinin I-AF350 (UEA I-AF350) is an AF350-labeled glehnia littoralis lectin I (UEA-I). Ulex Europaeus Agglutinin I exhibits specificity for cell surface glycoconjugates containing α-L-fucosylate. Ulex Europaeus Agglutinin I-AF350 can be used for vascular endothelial labeling, glycan imaging, and tissue staining studies (Ex/Em = 346/445 nm).
Fluorescent Dye  
/
HY-P0073S2 Tyr-Gly-{Gly-13C2,15N}-Phe-Met-OH TFA
Tyr-Gly-{Gly-13C2,15N}-Phe-Met-OH TFA (Met-Enkephalin-13C2,15N TFA-1) is the 13C- and 15N-labeled Tyr-Gly-Gly-Phe-Met-OH TFA. Tyr-Gly-Gly-Phe-Met-OH regulates human immune function and inhibits tumor growth via binding to the opioid receptor.
Isotope-Labeled Compounds   Opioid Receptor  
Cancer   Neurological, Eye or Ear Disease  
/
HY-170231 Bovine Osteopontin
Bovine Osteopontin (OPN) is a secreted highly acidic calcium-binding phosphorylated glycoprotein that is chemotactic for macrophages, smooth muscle cells, endothelial cells, and glial cells.
Biochemical Assay Reagents  
/
HY-P3995 Scospondistatin
Scospondistatin is an anti-angiogenic peptide that can inhibit proliferation and migration of human umbilical vein endothelial cells in vitro.
VEGFR  
Blood or Cardio-cerebrovascular Disease  
/
HY-P992086 Anti-Mouse VEGF Antibody (G6-31)
Anti-Mouse VEGF Antibody (G6-31) is a anti-mouse VEGF antibody. Anti-Mouse VEGF Antibody (G6-31) blocks VEGF-A-mediated angiogenesis and shows antitumor activity. Anti-Mouse VEGF Antibody (G6-31) can be used for the research of cancer, such as multiple endocrine neoplasia type 1.

Species: Mouse

VEGFR  
Cancer  
/
HY-P10052 CBO-P11
CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine dye bearing an alkyne function, allowing both “click” coupling on azido-modified nanoparticles and fluorescence labelling.
VEGFR  
/
HY-B0223S4 Albendazole-d3-1
Albendazole-d3-1 (SKF-62979-d3-1) is the deuterium labeled Albendazole (HY-B0223). Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, VEGF expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells.
Reactive Oxygen Species (ROS)  
/
HY-P3335 SU015
SU015 (DOTA-RGDfK dimer) is a Integrin αvβ5 and αvβ3 antagonist. SU015 exhibits comparable affinity for αvβ5 and αvβ3, with relatively higher potency and specificity compared to other integrins. SU015 inhibits αvβ3-mediated cell adhesion to fibrinogen, αvβ3-mediated adhesion of activated platelets to osteopontin, and αvβ5-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with 90Y (i.e., RP697) or 177Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors.
Integrin   Radionuclide-Drug Conjugates (RDCs)  
Cancer   Cardiovascular Disease  
/
HY-P11774 HYNIC-3P-RGD2
HYNIC-3P-RGD2 is a dimeric cyclic RGD peptide with high binding affinity for integrin αvβ3 (IC50 = 33 nM). HYNIC-3P-RGD2 acts as a precursor molecule for radiotracers and is used to detect tumor angiogenesis.
Integrin  
Cancer  
/
HY-10321G PD173074 (GMP)
PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer.
FGFR   TGF-beta/Smad  
Small Cell Lung Cancer  
/
HY-P992371 hPV19
hPV19 is a humanized inhibitory monoclonal antibody targeting vascular endothelial growth factor (VEGF) with a unique binding site. hPV19 can be used for the research of advanced solid tumors.

Species: Human

VEGFR  
Cancer  
/
HY-P10295 p53 (232-240)
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system.
MDM-2/p53  
/
HY-W782087A p-SCN-Bn-PCTA hydrochloride
p-SCN-Bn-PCTA hydrochloride is a Bifunctional Chelator used for radiometal labeling. p-SCN-Bn-PCTA hydrochloride can conjugate with peptides or antibodies via its isothiocyanate group. PCTA-RGD, formed by the conjugation of p-SCN-Bn-PCTA with cyclo-RGDyK, retains binding activity towards αvβ3 integrin with an IC50 of 1.8 μM. p-SCN-Bn-PCTA hydrochloride can be used for the construction of PET radiotracers and imaging studies related to pancreatic cancer, colorectal cancer, and tumor angiogenesis.
Biochemical Assay Reagents   Radionuclide-Drug Conjugates (RDCs)  
Colorectal Cancer   Pancreatic Cancer  
/
HY-P10550 VGB4
VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research.
VEGFR  
/
HY-187305S [U-15N]-PD-L1
[U-15N]-PD-L1 is the 15N-labeled PD-L1. PD-L1 is expressed on immune cells or aberrantly overexpressed on the surface of various tumor cells; it maintains immune tolerance and acts as a key molecule in tumor immune escape. This isotope can be used in NMR studies to investigate disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Cancer   Inflammation or Immune System Disease  
/
HY-P992511 CS2009
CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. CS2009 blocks the interactions of PD-1/PD-L1, CTLA-4/CD80 and VEGFA/VEGFR2, mediates checkpoint inhibition, and suppresses tumor angiogenesis. CS2009 reactivates PD-1/CTLA-4 double-positive tumor-infiltrating T lymphocytes, induces T cell activation, enhances tumor growth inhibition, promotes vascular normalization, improves T lymphocyte infiltration, and converts the immunosuppressive tumor microenvironment into an immunocompetent one. CS2009 can be used for the research of various advanced solid tumors.

Species: Human

PD-1/PD-L1   CTLA-4   VEGFR  
Cancer  
/
HY-W769991 Lactate sodium-13C2
Lactic acid-13C2 (DL-Lactic acid-13C2) sodium is the 13C-labeled Lactic acid sodium . Lactic acid (DL-Lactic acid) sodium is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid sodium is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid sodium is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid sodium also has antimicrobial activity, which can be used as a food preservative.
Isotope-Labeled Compounds   Bacterial   Hydroxycarboxylic Acid Receptor (HCAR)   Endogenous Metabolite  
Cancer  
/
HY-P11775 Peptide HRH
Peptide HRH is a polypeptide that specifically binds to VEGF receptors. Peptide HRH inhibits VEGF-stimulated endothelial cell proliferation. Peptide HRH inhibits angiogenesis and suppresses corneal neovascularization. Peptide HRH can be used in anti-angiogenesis related studies.
VEGFR  
Blood or Cardio-cerebrovascular Disease  
/
HY-16561G Resveratrol (GMP)
Resveratrol (GMP) is Resveratrol (HY-16561) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
DNA/RNA Synthesis   IKK   Autophagy   Mitophagy   Sirtuin   Apoptosis   Bacterial   Fungal   Keap1-Nrf2  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P992461 SHR-1802
SHR-1802 is a humanized anti-LAG-3 monoclonal antibody.SHR-1802 specifically binds to LAG-3 and inhibits its binding to major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin.SHR-1802 can be used for the research of advanced solid tumors.

Species: Human

LAG-3  
Cancer  
/
HY-B0312S1 Dipyridamole-d16
Dipyridamole-d16 is the deuterium labeled Dipyridamole. Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.
Phosphodiesterase (PDE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-W739948 Naltrexone-d3
Naltrexone-d3 is a deuterated labeled Naltrexone (HY-76711). Naltrexone is an antagonist of Opioid receptor. Naltrexone inhibits cell proliferation in vivo. Naltrexone reduces tumor growth by interfering with cell signalling and modifying the immune system.
Isotope-Labeled Compounds  
/
HY-B0239S2 Threo-Chloramphenicol-d6
Threo-Chloramphenicol-d6 is the deuterium labeled Chloramphenicol. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research.
JNK   Apoptosis   VEGFR   MMP   Bacterial   Akt   Autophagy   HIF/HIF Prolyl-Hydroxylase   Antibiotic   Beclin1  
/
HY-NP188 Lycopersicon esculentum (Tomato) Lectin (FITC)
Lycopersicon esculentum (Tomato) Lectin (FITC) is Lycopersicon esculentum (Tomato) Lectin (HY-NP071) labeled with FITC (HY-66019). Lycopersicon esculentum (Tomato) Lectin (FITC) binds to poly-N-acetyllactosamine oligosaccharides. Lycopersicon esculentum (Tomato) Lectin (FITC) is a major component of carbohydrates on the surface of endothelial and epithelial cells.
Fluorescent Dye   Biochemical Assay Reagents  
/
HY-D3181 CyGbPF
CyGbPF is a granzyme B-specific near-infrared fluorescent probe. CyGbPF can be cleaved by granzyme B to remove the peptide cage group, restoring near-infrared fluorescence. CyGbPF passively accumulates in mouse tumors, and its activated fluorescence correlates with granzyme B expression, CD8+ cytotoxic T lymphocyte populations, and CD4+ helper T lymphocyte populations in tumor tissues. CyGbPF is efficiently cleared by the kidneys, enabling the assessment of immune activation via optical urine analysis. CyGbPF allows real-time non-invasive evaluation of cancer immunotherapeutic efficacy in living animals. CyGbPF can be used in research on cancers such as breast cancer. Excitation wavelength/emission wavelength: approximately 658 nm/approximately 717 nm.
Fluorescent Dye   Caspase  
Breast Cancer  
/
HY-B0636S1 Triamcinolone acetonide-13C3
Triamcinolone acetonide-13C3 is the 13C-labeled Triamcinolone acetonide (HY-B0636). Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis.
Isotope-Labeled Compounds   FGFR   Glucocorticoid Receptor  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-NP090D Ulex Europaeus Agglutinin I-AF488
Ulex Europaeus Agglutinin I-AF488 (UEA I-AF488) is an AF488-labeled glehnia littoralis lectin I (UEA-I). Ulex Europaeus Agglutinin I exhibits specificity for cell surface glycoconjugates containing α-L-fucosylate. Ulex Europaeus Agglutinin I-AF488 can be used for vascular endothelial labeling, glycan imaging, and tissue staining studies (Ex/Em = 470/520 nm).
Fluorescent Dye  
/
HY-NP090C Ulex Europaeus Agglutinin I-AF405
Ulex Europaeus Agglutinin I-AF405 (UEA I-AF405) is an AF405-labeled glehnia littoralis lectin I (UEA-I). Ulex Europaeus Agglutinin I exhibits specificity for cell surface glycoconjugates containing α-L-fucosylate. Ulex Europaeus Agglutinin I-AF405 can be used for vascular endothelial labeling, glycan imaging, and tissue staining studies (Ex/Em = 405/435 nm).
Fluorescent Dye  
/
HY-N0191S Andrographolide-d
Andrographolide-d (Andrographis-d) is the deuterium labeled Andrographolide (HY-N0191). Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
Isotope-Labeled Compounds   Influenza Virus   SARS-CoV   Parasite   NF-κB   Autophagy  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-B1448AS (Rac)-Benidipine-d7
(Rac)-Benidipine-d7 is the deuterium labeled Benidipine. Benidipine is a potent and orally active calcium channel antagonist. Benidipine shows anti-apoptosis effects in ischaemic/reperfused myocardial cells. Benidipine increases the activity of endothelial cell-type nitric oxide synthase and improves coronary circulation in hypertensive rats.
Apoptosis   Calcium Channel  
Blood or Cardio-cerebrovascular Disease  
/
HY-B1637S Ditiocarb-d10 sodium
Ditiocarb-d10 sodium (Sodium diethyldithiocarbamate-d10) is the deuterium labeled Ditiocarb sodium (HY-B1637). Ditiocarb sodium (Sodium diethyldithiocarbamate) is an orally active copper reagent. Ditiocarb sodium exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium can be used in the research of tumors, inflammatory, and immune-related diseases.
Isotope-Labeled Compounds   HIV   Biochemical Assay Reagents  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P4903 RGD-targeted Proapoptotic Peptide
RGD-targeted Proapoptotic Peptide is a peptide. The C-terminal RGD-4C peptide (ACDCRGDCFC) binds preferentially to integrins at sites of tumor angiogenesis.
Others  
/
HY-P991384 DX-2240
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors).

Species: Human

Tie  
Cancer  
/
HY-165394 Melafolone
Melafolone is a potent dual COX-2/EGFR inhibitor with IC50s of 13.2 μM (COX-2) and 17.4 μM (EGFR). Melafolone enhances the effect of anti-PD-1 through vascular normalization and PD-L1 downregulation via the PI3K/Akt pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone can be used for lung cancer research.
COX   EGFR   PD-1/PD-L1   PI3K   Akt  
/
HY-P992323 BI-836880
BI-836880 is a humanized bispecific nanobody and a selective inhibitor of VEGF and ANG2, with a Kd of 16 pM for hANG2, an EC50 of 1.4 nM for VEGF165, and an EC50 of 2.3 nM for VEGF121. BI-836880 blocks ERK phosphorylation downstream of VEGF-A as well as TIE2 phosphorylation downstream of ANG2. BI-836880 does not inhibit ANG1-mediated TIE2 phosphorylation. BI-836880 exerts anti-angiogenic effects, reduces the number of immature endothelial vessels in tumor tissues, and inhibits tumor growth in preclinical models. BI-836880 can be used in the research of pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, colon cancer, and Lewis lung cancer.

Species: Human

VEGFR   Tie   ERK  
Blood or Cardio-cerebrovascular Disease   Colorectal Cancer   Pancreatic Cancer   Ovarian Cancer   Non-Small Cell Lung Cancer   Renal Cancer  
/
HY-W744272 Estetrol-d3
Estetrol-d3 is the deuterium labeled Estetrol (HY-15731). Estetrol, an orally active estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear?estrogen receptor?modulator. Estetrol binds?ERα?as well as?ERβ?(with a fourfold lower affinity). Estetrol increases?eNOS?expression/activity and NO synthesis in endothelial cells. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast. Estetrol can be used in contraception and menopausal hormone research.
Isotope-Labeled Compounds   NO Synthase   Endogenous Metabolite   Estrogen Receptor/ERR  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-N0545S2 Taurocholic acid-d4-1 sodium
Taurocholic acid-d4-1 sodium (Sodium taurocholate-d4-1) is the deuterium labeled Taurocholic acid sodium (HY-N0545). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
Isotope-Labeled Compounds   Endogenous Metabolite   VEGFR  
/
HY-110066R (Z)-Guggulsterone (Standard)
(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis. (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection.
Reference Standards   Apoptosis   VEGFR   Akt   Angiotensin-converting Enzyme (ACE)   SARS-CoV   FXR  
Cancer   SARS-CoV-2 Infection  
/
HY-P10323 T7 Peptide
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma.
Integrin   FAK   mTOR   Apoptosis  
Cancer  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-P1789 CTTHWGFTLC, CYCLIC
CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM.
MMP  
Inflammation or Immune System Disease  
/
HY-P0316 TP508
TP508 is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 activates endothelial cells and stem cells to revascularize and regenerate tissues.
Thrombin   NO Synthase  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991423 MEDI0639
MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research.

Species: Human

Notch  
Respiratory Disease   Small Cell Lung Cancer  
/
HY-107818R 4-Hydroxychalcone (Standard)
4-Hydroxychalcone (Standard) is the analytical standard of 4-Hydroxychalcone (HY-107818). This product is intended for research and analytical applications. 4-Hydroxychalcone is an orally active flavonoid precursor. 4-Hydroxychalcone inhibits VEGF- and bFGF-induced phosphorylation of ERK1/2 and Akt. 4-Hydroxychalcone suppresses resistant hypertension by alleviating hyperaldosteronism, inflammation and renal injury in cryptochrome gene knockout mice. 4-Hydroxychalcone possesses anti-angiogenic activity.
Reference Standards   ERK   Akt  
Inflammation or Immune System Disease   Renal Disease   hCoV-OC43   Hypertension   Atrial Fibrillation  
/
HY-P991309 ZM-008
ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors.

Species: Human

C-type Lectin-like Receptors (CTLRs)  
Cancer  
/
HY-W015912S 2-Acetylfuran-d3
2-Acetylfuran-d3 is deuterated labeled Citreoviridin (HY-N6745). Citreoviridin, a toxin from Penicillium citreoviride NRRL 2579, inhibits brain synaptosomal Na+/K+-ATPase whereas in microsomes, both Na+/K+-ATPase and Mg2+-ATPase activities are significantly stimulated in a dose-dependent manner. Citreoviridin inhibits cell proliferation and enhances apoptosis of human umbilical vein endothelial cells.
Isotope-Labeled Compounds  
/
HY-B1788S2 Taurocholic acid-d5
Taurocholic acid-d5 (Taurocholic Acid-d5) is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect.
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-B0331S1 Enalapril-d3
Enalapril-d3 (MK-421-d3) is the deuterated-labeled Enalapril (HY-B0331). Enalapril is an orally active angiotensin-converting enzyme inhibitor. Enalapril blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology.
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)   Apoptosis   Reactive Oxygen Species (ROS)  
Cerebrovascular Disease   Glucose Metabolism   Alzheimer's Disease   Hypertension   Myocardial Infarction   Heart Failure   Atrial Fibrillation  
/
HY-76520S Sitaxsentan-13C6
Sitaxsentan-13C6 (IPI 1040-13C6) is 13C labeled Sitaxsentan (HY-76520). Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension.
Isotope-Labeled Compounds   Endothelin Receptor   TGF-β Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P990174 Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32)
Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is an anti-mouse Pan-endothelial Cell Antigen/MECA-32 IgG2a monoclonal antibody. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) can label endothelial cells. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is often used for immunohistochemistry, delivery of siRNA and immunofluorescence.

Species: Mouse

Others  
/
HY-W653893 Taurocholic acid-d5 sodium
Taurocholic acid-d5 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
Isotope-Labeled Compounds   Endogenous Metabolite   VEGFR  
Inflammation or Immune System Disease  
/
HY-P991896 AT1412
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells.

Species: Human

Transmembrane Glycoprotein  
Gastric Cancer   Pancreatic Cancer   Cancer Immunology   Immunotherapy for Colorectal Cancer   Acute Lymphoblastic Leukemia   Immunotherapy for Melanoma  
/
HY-Y0121S1 Ethyl cinnamate-d7
Ethyl cinnamate-d7 is deuterated labeled Ethyl cinnamate (HY-Y0121). Ethyl cinnamate, an orally active chemical constituent of the rhizome of Kaempferia galanga, exhibits anti-cancer, nematocidal, sedative and vasorelaxant activities. Ethyl cinnamate is a fragrance ingredient used as a food flavor and additive for cosmetic products. Ethyl cinnamate is also an excellent clearing reagent for mammalian tissues. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in colorectal cancer. Ethyl cinnamate inhibits the tonic contractions induced by high K+ and phenylephrine (PE) with respective IC50 values of 0.30 mM and 0.38 mM in rat aorta.
Isotope-Labeled Compounds  
/
HY-113046S1 5-Methyltetrahydrofolic acid-13C6
5-Methyltetrahydrofolic acid-13C6 (5-Methyl THF-13C6) is 13C labeled 5-Methyltetrahydrofolic acid. 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases.
Isotope-Labeled Compounds   Endogenous Metabolite  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-N15264 Azaspirene
Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2).

Source: Neosartorya sp.

VEGFR   Raf  
Cancer  
/
HY-P9994 Pertuzumab zuvotolimod
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research.
Antibody-Drug Conjugates (ADCs)   EGFR   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease  
/
HY-B0312S Dipyridamole-d20
Dipyridamole-d20 is the deuterium labeled Dipyridamole. Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.
Phosphodiesterase (PDE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-N0587R Demethylzeylasteral (Standard)
Demethylzeylasteral (Standard) is the analytical standard of Demethylzeylasteral. This product is intended for research and analytical applications. Demethylzeylasteral is an orally active triterpenoid compound isolated from Tripterygium wilfordii, which has functions such as anti-inflammatory, anti-tumor, anti fertility, estrogen metabolism regulation, immune suppression, and immune system regulation .
Reference Standards   Apoptosis   TGF-beta/Smad   Estrogen Receptor/ERR   NF-κB   FAK  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P1789A CTTHWGFTLC, CYCLIC TFA
CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM.
MMP  
Inflammation or Immune System Disease  
/
HY-P10553A ARF(26-44), cell-permeable acetate
ARF(26-44), cell-permeable acetate is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26-44) cell-permeable acetate shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26-44), cell-permeable acetate can be used in research on tumor therapy.
FOXM1   Apoptosis  
Cancer  
/
HY-P10496A MAGE-A1-derived peptide acetate
MAGE-A1-derived peptide acetate is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide acetate can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide acetate can be used in the study of tumor immunity.
Others  
/
HY-D1056B2 Lipopolysaccharides, from Proteus mirabilis
Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-P10971 Nef-M1
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, p-GSK-3β and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer.
CXCR   Apoptosis   VEGFR   GSK-3   Cadherin   Caspase  
/
HY-78131S3 Ibuprofen-13C6
Ibuprofen-13C6 ((±)-Ibuprofen-13C6) is a 13C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.
Isotope-Labeled Compounds   COX   Parasite   Apoptosis  
Cancer  
/
HY-P10553 ARF(26-44), cell-permeable
ARF(26-44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26-44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26-44), cell-permeable can be used in research on tumor therapy.
FOXM1   Apoptosis  
Cancer  
/
HY-113046S2 5-Methyltetrahydrofolic acid-d4
5-Methyltetrahydrofolic acid-d4 (5-Methyl THF-d4) is the deuterium labeled 5-Methyltetrahydrofolic acid (HY-113046). 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-P992201 Anti-CD160 Antibody (MAT 302)
Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma.

Species: Human

MHC   Apoptosis   IFNAR   TNF Receptor   Interleukin Related   Akt   mTOR  
Blood or Cardio-cerebrovascular Disease   Melanoma   Retinopathy  
/
HY-128922S Dexamethasone palmitate-d31
Dexamethasone palmitate-d31 is the deuterium labeled Dexamethasone palmitate(HY-128922).Dexamethasone palmitate (DXP) is a proagent of Dexamethasone (HY-14648). Dexamethasone palmitate can be used for the research of inflammation.
Isotope-Labeled Compounds   Sodium Channel  
Inflammation or Immune System Disease  
/
HY-N15497 Terpestacin
Terpestacin is found in Phoma exigua var. heteromorpha. Terpestacin binds to UQCRB to inhibit the production of mitochondrial ROS and HIF-1α. Terpestacin inhibits tumor angiogenesis in the FM3A breast cancer cell xenograft mouse model. Terpestacin has antitumor activity and phytotoxicity.

Source: Phoma exigua var. heteromorpha

Reactive Oxygen Species (ROS)   HIF/HIF Prolyl-Hydroxylase  
/
HY-P99035 Naptumomab
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma.

Species: Human

Others  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Luminal Breast Cancer   Triple-Negative Breast Cancer  
/
HY-B0633E Hyaluronic acid, low endotoxin
Hyaluronic acid, low endotoxin (Hyaluronan, low endotoxin) is a biopolymer composed of repeating disaccharide units containing low levels of endotoxin. Hyaluronic acid is a major component of the extracellular matrix (ECM). It is synthesized on the plasma membrane. Hyaluronic acid exerts its effects by binding to receptors CD44 and RHAMM. Hyaluronic acid activates PI3K-Akt signaling. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting or stimulating the binding of proteolytic MMP-9 to the cell surface. Elevated hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion, and angiogenesis in digestive system cancers. Hyaluronic acid is involved in tissue remodeling and rapid cell proliferation in several physiological processes, including embryonic morphogenesis and wound healing. Hyaluronic acid can be used as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid can be used as a drug delivery carrier for sodium butyrate, enhancing its anti-proliferative activity against breast cancer cell lines. Hyaluronic acid can lubricate the corneal endothelium. Hyaluronic acid can improve tissue hydration and enhance the resistance of cells to mechanical damage. Hyaluronic acid has been conjugated with antibodies to ensure that the active compound continues to exert its effects at the site of inflammation. Hyaluronic acid can be used in research in the fields of osteoarthritis, ophthalmology, cosmetic dermatology, oncology, and liver diseases.
Endogenous Metabolite   CD44   Bacterial   Akt   PI3K  
Cancer   Inflammation or Immune System Disease   Visual System Disease   Liver Disease   Osteoarthritis  
/
HY-P4641 H-Trp-Phe-OH
H-Trp-Phe-OH (Trp-Phe) is an ACE inhibitor and endothelial function regulator, with an ACE IC50 of 0.318 mg/mL. H-Trp-Phe-OH increases nitric oxide concentration, reduces endothelin-1 (ET-1) levels, and reverses norepinephrine-mediated endothelial cell dysfunction. H-Trp-Phe-OH exhibits antihypertensive activity. H-Trp-Phe-OH can be used in studies related to hypertension and atherosclerosis.
Angiotensin-converting Enzyme (ACE)   Endothelin Receptor  
Hypertension  
/
HY-P990082 Suvemcitug
Suvemcitug (APX-003) is a selective humanized rabbit monoclonal IgG1 (κ) anti-VEGF antibody. Suvemcitug inhibits the binding of VEGF to purified VEGFR1 (IC50 = 21.0 ng/mL) and VEGFR2 (IC50 = 275.4 ng/mL). Suvemcitug suppresses tumor angiogenesis, tumor growth and metastasis. Suvemcitug is applicable to research related to epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

Species: Human

VEGFR  
Blood or Cardio-cerebrovascular Disease   Epithelial Ovarian Cancer  
/
HY-P11775A Peptide HRH acetate
Peptide HRH acetate is a polypeptide that specifically binds to VEGF receptors. Peptide HRH acetate inhibits VEGF-stimulated endothelial cell proliferation. Peptide HRH acetate inhibits angiogenesis and suppresses corneal neovascularization. Peptide HRH acetate can be used in anti-angiogenesis related studies.
VEGFR  
Cardiovascular Disease  
/
HY-P99516 Vulinacimab
Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer.

Species: Human

VEGFR  
Non-Small Cell Lung Cancer  
/
HY-W653842 Taurocholic acid-d8 sodium
Taurocholic acid-d8 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
Isotope-Labeled Compounds   Endogenous Metabolite   VEGFR  
Inflammation or Immune System Disease  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-N2666 5α-Hydroxycostic acid
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and Ang2/Tie2 pathways.
VEGFR  
Lung Cancer   Breast Cancer   Colorectal Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Obesity   Lung Fibrosis  
/
HY-P99540 Tuvonralimab
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CTLA-4  
Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-W134005 Mg(Ⅱ)-EDTA disodium tetrahydrate
Mg(Ⅱ)-EDTA (Ethylenediaminetetraacetic acid magnesium) disodium tetrahydrate is a divalent metal chelator and ferroptosis inducer. Mg (Ⅱ)-EDTA disodium tetrahydrate reduces E-cadherin expression by chelating Ca2+ on the surface of tumor cells, thereby triggering cell dissociation and inducing epithelial-mesenchymal transition (EMT). Mg (Ⅱ)-EDTA disodium tetrahydrate further chelates lysosomal iron to form EDTA-Fe, induces ferroptosis through the Fenton reaction, and synergistically enhances immune responses to inhibit tumor metastasis. Mg (Ⅱ)-EDTA (disodium tetrahydrate) can be used in tumor-related research.
Ferroptosis   Cadherin  
/
HY-P991023 Safimestomig
Safimestomig (6MW3211) is an CD47/PD-L1-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer.

Species: Human

CD47   PD-1/PD-L1  
Cancer  
/
HY-P991795 Anti-Mouse/Human CXCL12 Antibody (K15C)
Anti-Mouse/Human CXCL12 Antibody (K15C) is an antibody targeting SDF-1/CXCL12. Anti-Mouse/Human CXCL12 Antibody (K15C) blocks the biological activity of SDF-1 secreted by cancer-associated fibroblasts. Anti-Mouse/Human CXCL12 Antibody (K15C) inhibits tumor growth, reduces tumor microvessel density, and decreases the proportion of Sca1+CD31+ endothelial progenitor cells in tumors. Anti-Mouse/Human CXCL12 Antibody (K15C) can be used for research on aggressive human breast cancer. The recommended isotype control is Mouse IgG2a kappa, Isotype Control (HY-P99978).

Species: Mouse/Human

CXCR  
Breast Cancer  
/
HY-P3369 Gersizangitide
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGF receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis.
VEGFR   Tie   Akt  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-NP0190 Ulex Europaeus Agglutinin I (Biotinylated)
Ulex Europaeus Agglutinin I Biotinylated (UEA I Biotinylated) is a biotinylated lectin that binds to α1,2-fucosylated proteins and cell-surface glycoconjugates containing α-L-fucose. Ulex Europaeus Agglutinin I Biotinylated serves as a histochemical marker for endothelial cells.
Fluorescent Dye  
/
HY-124404A 12(S)-HETE
12(S)-HETE is a metabolite of Arachidonic acid, AA (HY-109590). 12(S)-HETE promotes ERK and P38 MAPK phosphorylation, stimulates DNA synthesis and cell proliferation in cancer cells. 12(S)-HETE facilitates wound healing of injured murine-lung-derived microvascular endothelial cell monolayers. 12(S)-HETE can be used for the research of pancreatic cancer.
ERK   p38 MAPK   DNA/RNA Synthesis  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P99409 Oregovomab
Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells.

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-P10493A NY-ESO-1 (157-165) peptide TFA
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
Amino Acid Derivatives  
/
HY-W011398 Linoleate sodium
Linoleate sodium is an orally active IL8 regulator via the JNK and NF-κB pathway. Linoleate sodium can change the composition of fatty acids and the production of metabolites in cells. Linoleate sodium has anti-inflammatory, immune-regulating, and tumor cell growth-affecting activities.
Environmental Pollutants   Parasite   Apoptosis   NF-κB   Interleukin Related   JNK  
Metabolic or Endocrine Disease   Pancreatic Cancer   Pain   Digestive System Inflammation  
/
HY-128749A D-Glucaric acid tetrahydrate
D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases.
Endogenous Metabolite   Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N6772 Cytochalasin E
Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. Cytochalasin E is a potent actin depolymerization agent, and it binds and caps the barbed end of actin filaments to prevent actin elongation.

Source: the fungus R. necatrix

Autophagy  
Cancer   Obesity  
/
HY-P10420 RS17
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.
CD47   Interleukin Related  
Cancer  
/
HY-N6073 Soyasapogenol A
Soyasapogenol A is a triterpenoid aglycone of soyasaponins. Soyasapogenol A has activities such as anti-inflammation, anti-cancer, hepatoprotection and anti-HSV-1. Soyasapogenol A can be used in the research of tumors and immune inflammatory diseases.
Apoptosis   HSV  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Viral Infection   Digestive System Inflammation  
/
HY-B2227BS Lactic acid-d4 sodium (60% w/w in water)
Lactic acid-d4 (DL-Lactic acid-d4) sodium (60% in water) is the deuterium labeled Lactic acid sodium (60% in water) (HY-B2227B) . Lactic acid (DL-Lactic acid) sodium (60% w/w in water) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid sodium (60% w/w in water) is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid sodium (60% w/w in water) is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid sodium (60% w/w in water) also has antimicrobial activity, which can be used as a food preservative.
Isotope-Labeled Compounds   Bacterial   Hydroxycarboxylic Acid Receptor (HCAR)   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N4127 3'-Demethylnobiletin
3'-Demethylnobiletin, a derivative of Nobiletin, is a polymethoxyflavonoid in citrus fruits. Nobiletin exhibits anticancer activity and inhibits tumor angiogenesis by regulating Src, FAK, and STAT3 signaling.
Src   STAT  
Inflammation or Immune System Disease   Lung Cancer   Pancreatic Cancer   Pain   Obesity  
/
HY-N0183R Formononetin (Standard)
Formononetin (Standard) is the analytical standard of Formononetin. This product is intended for research and analytical applications. Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.
Reference Standards   FGFR   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P99510 Zansecimab
Zansecimab (LY-3127804) is a monoclonal antibody against angiopoietin 2 (Ang‑2). Zansecimab can be used in research on angiogenesis, immunomodulation and anti-tumor activity.

Species: Human

Tie  
Cancer   Inflammation or Immune System Disease  
/
HY-P991449 LY3415244
LY3415244 is a bispecific antibody that targets and inhibits TIM-3 and PD-L1. LY3415244 blocks the interaction between TIM-3 on immune cells and PD-L1 on the surface of tumor cells, establishes intercellular connections between TIM-3-positive immune cells and PD-L1-positive tumor cells, and blocks dual immunosuppressive signals. LY3415244 alleviates T cell exhaustion and restores T cell proliferation. LY3415244 induces broad-spectrum anti-drug antibodies, which impairs the binding capacity to soluble TIM-3 targets. LY3415244 can be used in research related to various advanced solid tumors.

Species: Human

PD-1/PD-L1   Tim3  
Cancer  
/
HY-P2452 Vitronectin (367-378)
Vitronectin (367-378) is a peptide corresponding to residues 367-378 of Vitronectin. Vitronectin is a multifunctional glycoprotein known in several human tumors for its adhesive role in processes such as cell growth, angiogenesis and metastasis.
Integrin  
Cancer  
/
HY-P3695 VSPPLTLGQLLS
VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation.
FGFR  
Lung Cancer   Prostate Cancer   Liver Cancer  
/
HY-P11303 PADRE peptide
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.
CD74   MHC  
Cervical Cancer   Glioblastoma  
/
HY-159067 DEAE-dextran, MW 500000 hydrochloride
DEAE-dextran, MW 500000 hydrochloride (DEAE-dextran, MW 500000 hydrochloride, from bacterial (Leuconostoc mesenteroides)) is a high-molecular-weight positively charged polymer that significantly enhances the uptake of viral RNA by tissue culture cells. When employed in the delivery system for "tumor immunity" RNA-splenocyte transfer, DEAE-dextran can markedly extend the lifespan of tumor-bearing animals, comparable to that of actively immunized animals. Furthermore, DEAE-dextran serves as a complexing agent for nucleic acids, forming composite particles with DNA/RNA for extensive applications in gene delivery. Additionally, DEAE-dextran can be utilized as a coating for liposomes.
Biochemical Assay Reagents  
Cancer  
/
HY-B2227BS1 Lactic acid-d3 sodium (60% w/w in water)
Lactic acid-d3 (DL-Lactic acid-d3) sodium (60% in water) is the deuterium labeled Lactic acid sodium (60% in water) (HY-B2227B) . Lactic acid (DL-Lactic acid) sodium (60% w/w in water) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid sodium (60% w/w in water) is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid sodium (60% w/w in water) is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid sodium (60% w/w in water) also has antimicrobial activity, which can be used as a food preservative.
Isotope-Labeled Compounds   Bacterial   Hydroxycarboxylic Acid Receptor (HCAR)   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-59208 4-Quinolinol
4-Quinolone (Kynurine) is a quinoline derivative. Kynurine pathway modulates tryptophan metabolism and involves in neuroprotective effect. Kynurine promotes tumor cell survival and motility by suppressing antitumor immune.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease  
/
HY-N0859 Schisanhenol
Schisanhenol (Schizanhenol), a lignan, is an orally active antioxidant. Schisanhenol reduces AChE activity, increases SIRT1 and PGC-1α expression, and decreases phosphorylated Tau (Ser 396) levels. Schisanhenol increases SOD and glutathione peroxidase activity, decreases malondialdehyde (MDA) content, and inhibits UGT2B7 activitY. Schisanhenol attenuates ox-LDL-induced apoptosis, intracellular reactive oxygen species generation, and cytotoxicity in endothelial cells. Schisanhenol inhibits LDL oxidation, brain mitochondrial and membrane peroxidative damage, and brain mitochondrial swelling and disintegration. Schisanhenol can be used for the research of Alzheimer’s disease, atherosclerosis, brain ischemia, and age-related brain deterioration.
UGT   Cholinesterase (ChE)   Tau Protein   SOD   Sirtuin  
Cancer   Alzheimer's Disease   Atherosclerosis and Inflammation  
/
HY-P990961 Palverafusp alfa
Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer.

Species: Human

VEGFR   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-N0637A (±)-Eriodictyol
(±)-Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC50=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. (±)-Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. (±)-Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. (±)-Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. (±)-Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases.
Melanocortin Receptor   TRP Channel  
Metabolic or Endocrine Disease  
/
HY-N3677 Dammarenediol II
Dammarenediol II is a ginsenoside precursor. Dammarenediol II reduces the activity of O-GlcNAc transferase (OGT) and downregulates the global O-GlcNAcylation level. Dammarenediol II inhibits the phosphorylation of Akt, mTOR and GSK3β. Dammarenediol II inhibits human carboxylesterase activity, VEGF-induced ROS production, stress fiber formation and vascular endothelial cadherin disruption. Dammarenediol II promotes cell apoptosis (apoptosis), increases the levels of cleaved PARP1 and p53, and inhibits retinal microvascular leakage. Dammarenediol II can be used in studies related to liver cancer and diabetic retinopathy.
OGT   Akt   mTOR   GSK-3   Reactive Oxygen Species (ROS)   Apoptosis   PARP   MDM-2/p53  
Liver Cancer   Autoimmune Disease  
/
HY-P991739 RC148
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer.

Species: Human

VEGFR   PD-1/PD-L1  
Gastric Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
/
HY-N2147 Phorbol
Phorbol is the flagship member of the tigliane diterpene family. Phorbol can be isolated from natural sources and through semisynthesis. Phorbol can form esters that have a wide array of biological properties, which includes the induction of angiogenesis in vitro and promoting tumor in vivo.
Others  
Cancer  
/
HY-P99057 Varlilumab
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

Species: Human

TNF Receptor   Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P10580A Vasculotide TFA
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury.
Cadherin   PI3K   Claudin   Tie   Akt  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P10831 GNQWFI
GNQWFI, an anti-Flt1 peptide, is a VEGFR1-specific antagonist. GNQWFI blocks the interaction of VEGFR1 with various VEGFR1 ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF) and inhibits VEGF-induced endothelial cell migration and tube formation. GNQWFI is promising for research of cancer, asthma, and other ocular diseases.
VEGFR  
Lung Cancer   Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Cardiovascular Disease   Lung Fibrosis  
/
HY-137874 L-Glutamic γ-monohydroxamate
L-Glutamic γ-monohydroxamate is an antitumor agent, inhibits cell proliferation. L-Glutamic γ-monohydroxamate selectively inhibits the uptake of L-histidine into microvascular endothelial cell. L-Glutamic γ-monohydroxamate, as a vanadium ligand, activates glucose uptake and metabolism, thus decreases the blood glucose levels in vivo.
Others  
Cancer   Glucose Metabolism  
/
HY-W010697 Cholesteryl linoleate
Cholesteryl linoleate is a cholesteryl ester with antibacterial activity that is present in low-density lipoprotein (LDL) particles, human nasal fluid, and respiratory epithelial secretions. Cholesteryl linoleate is oxidized by 12/15-lipoxygenase in macrophages and participates in selective uptake and efflux via LDL receptor-related protein. Cholesteryl linoleate does not induce endothelial adhesion molecule expression, nor does it induce monocyte binding to endothelial cells. Cholesteryl linoleate liposomal formulations inhibit the growth of multiple bacteria at physiological nasal fluid concentrations and act synergistically with antimicrobial peptides. Cholesteryl linoleate is useful for research related to atherosclerosis and bacterial infections.
Endogenous Metabolite   Bacterial  
Metabolic or Endocrine Disease   Bacterial Infection   Atherosclerosis and Inflammation  
/
HY-P99215 Parsatuzumab
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition.

Species: Human

VEGFR  
Cancer  
/
HY-P10586A Macrophage-activating lipopeptide 2 TFA
Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL).
Toll-like Receptor (TLR)   NO Synthase  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-P990832 Anti-MHC Class I Antibody (W6/32)
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human MHC Class I. Anti-MHC Class I Antibody (W6/32) reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. Anti-MHC Class I Antibody (W6/32) increases adherence of monocytes to human endothelial cells. Anti-MHC Class I Antibody (W6/32) can be used for the research of immunology.

Species: Human

MHC  
Inflammation or Immune System Disease  
/
HY-B2227R Lactic acid (Standard)
Lactic acid (Standard) (DL-Lactic acid (Standard)) is the analytical standard of Lactic acid (HY-B2227). This product is intended for research and analytical applications. Lactic acid (DL-Lactic acid) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator and an epigenetic modulator inducing lysine residues lactylation. Lactic acid is a glycolysis end-product, bridging the gap between glycolysis and oxidative phosphorylation. Lactic acid is an oncometabolite and has immune protective role of lactate in anti-tumor immunity. Lactic acid also has antimicrobial activity, which can be used as a food preservative.
Reference Standards   Bacterial   Hydroxycarboxylic Acid Receptor (HCAR)   Endogenous Metabolite  
Cancer   Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P10580 Vasculotide
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury.
Tie   PI3K   Akt   Cadherin   Claudin  
Infection   Blood or Cardio-cerebrovascular Disease   Skin Inflammation  
/
HY-P10493 NY-ESO-1 (157-165) peptide
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
Amino Acid Derivatives  
/
HY-P3267A Apo-Bovine Transferrin
Apo-Bovine Transferrin refers to iron free Transferrin (HY-P3267), serves as Transferrin receptor ligand and mediates iron release from endothelial cells. Apo-Transferrin can directly bind to hephaestin, which can convert Fe2+ to Fe3+. Apo-Transferrin mediates iron efflux most likely in cooperation with ferroportin 1. Apo-Bovine Transferrin can be used in neuroretinal research.
Ferroportin   Transferrin Receptor  
Neurological, Eye or Ear Disease  
/
HY-P99036 Nesvacumab
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches.

Species: Human

Tie  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P5423 GALA
GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. GALA significantly promotes the cytosolic release of cargos carried by exosomes, plasmids and liposomes, effectively enhances gene transfection efficiency, and drives gene knockdown of functional macromolecules (such as siRNA) in alveolar epithelial cells (with no significant cytotoxicity at effective concentrations). GALA serves as a critical tool for studies on lung cancer metastasis (e.g., melanoma lung metastasis) and lung-targeted drug delivery systems.
Exosomes   Liposome  
Metastatic Melanoma  
/
HY-171821 PF-08046054
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors
Antibody-Drug Conjugates (ADCs)   PD-1/PD-L1  
Cancer  
/
HY-D1872 800CW NHS ester
800CW NHS ester is a near-infrared fluorescent dye active ester that can conjugate with amine-containing small molecules, antibodies, peptides, and other substances to form fluorescent conjugates. 800CW NHS ester exhibits high fluorescence quantum yield and low non-specific binding properties. 800CW NHS ester can be used in biomedical research such as microbial infection imaging, tumor imaging, and biochemical detection.
Fluorescent Dye  
/
HY-P6292A KS-133 TFA
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation.
PACAP Receptor  
Cancer   Neurological, Eye or Ear Disease   Immunomodulation  
/
HY-P99041A Panitumumab (anti-EGFR)
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer.

Species: Human

EGFR  
Colorectal Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
/
HY-P5558 KLTWQELYQLKYKGI
KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair.
VEGFR  
Neurological, Eye or Ear Disease  
/
HY-P1120 WKYMVm
WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor.
Formyl Peptide Receptor (FPR)   PERK   Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
/
HY-W020780 mPEG5000-Mal
mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses.
Biochemical Assay Reagents  
/
HY-P73556 VEGF145 Protein, Human (HEK293, solution)
VEGF145 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF145 Protein, Human (HEK293) is the recombinant human-derived VEGF145 protein, expressed by HEK293 , with tag free. The total length of VEGF145 Protein, Human (HEK293) is 145 a.a., with molecular weight of ~16.92 kDa.

Species: Human; Source: HEK293

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

/
HY-P70519 VEGF121 Protein, Human (HEK293, His)
VEGF121 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (121a.a, HEK293, His) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF121 Protein, Human (121a.a, HEK293, His) is 121 a.a., with molecular weight of 16-18 kDa.

Species: Human; Source: HEK293

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

/
HY-P700496 VEGF-A Protein, Rabbit (His-SUMO)
The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (His-SUMO) is the recombinant Rabbit-derived VEGF-A protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Rabbit; Source: E. coli

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

/
HY-P7110G GMP VEGF165 Protein, Human
GMP VEGF165 Protein, Human is a Vascular Endothelial Growth Factor A (VEGF-A) isoform. VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis.

Species: Human; Source: E. coli

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

/
HY-P70638 VEGF164 Protein, Rat (P.pastoris)
The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (P.pastoris) is the recombinant rat-derived VEGF164 protein, expressed by P. pastoris , with tag free and A36T mutation.

Species: Rat; Source: P. pastoris

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

/
HY-P702553 SREC-I/SCARF1 Protein, Human (HEK293, His)
SREC-I/SCARF1 Protein acts as a multifunctional mediator, facilitating Ac-LDL binding and degradation, suggesting a role in lipid metabolism and adhesion. Involved in neurite-like outgrowth, it interacts with SREC2 and AVIL, forming a complex molecular network. The protein's diverse roles underscore its significance in various cellular processes beyond lipid metabolism. SREC-I/SCARF1 Protein, Human (HEK293, His) is the recombinant human-derived SREC-I/SCARF1 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins

/
HY-P77279 VEGF183 Protein, Human (sf9)
VEGF183 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF183 Protein, Human (sf9) is the recombinant human-derived VEGF183 protein, expressed by Sf9 insect cells , with tag free. The total length of VEGF183 Protein, Human (sf9) is 183 a.a., with molecular weight of ~21 KDa.

Species: Human; Source: Sf9 insect cells

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

/
HY-P703971 VEGF110 Protein, Human (HEK293)
Vascular Endothelial Growth Factor A (VEGF-A) is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF110 Protein, Human (HEK293) is the recombinant human-derived VEGF110 protein, expressed by HEK293, with tag free.

Species: Human; Source: HEK293

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

/
HY-P703478 VEGF165 Protein, Human (HEK293, StrepⅡ, His)
VEGF165 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF165 Protein, Human (HEK293, Strep, His) is the recombinant human-derived VEGF165, expressed by HEK293, with Strep, His labeled tag.

Species: Human; Source: HEK293

/
HY-P704409 VEGF121 Protein, Human (HEK293, N-His)
Vascular Endothelial Growth Factor A (VEGF-A) is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (HEK293, N-His) is the recombinant human-derived VEGF121 protein, expressed by HEK293, with N-His labeled tag.

Species: Human; Source: HEK293

Cytokines and Growth Factors VEGF & VEGFR VEGF VEGF-A

/
HY-P80928 VEGF Receptor 1 Antibody (YA015)
VEGF Receptor 1 Antibody (YA015) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF Receptor 1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86376 VEGFA Antibody (YA6068)
VEGFA Antibody (YA6068) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGFA.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80370 VEGF Receptor 2 Antibody (YA014)
VEGF Receptor 2 Antibody (YA014) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF Receptor 2.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84117 VEGFA Antibody (YA3814)
VEGFA Antibody (YA3814) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to VEGFA.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P85795 VEGFA Antibody (YA5487)
VEGFA Antibody (YA5487) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to VEGFA.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P80928A VEGF Receptor 1 Antibody (YA015)(PBS only)
VEGF Receptor 1 Antibody (YA015) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF Receptor 1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80929A VEGFA Antibody (YA013)(PBS only)
VEGFA Antibody (YA013) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGFA.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82882 VEGFB Antibody (YA2627)
VEGFB Antibody (YA2627) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGFB.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84117A VEGFA Antibody (YA3814)(PBS only)
VEGFA Antibody (YA3814) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to VEGFA.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

Cell Biology Cell Culture Cell Transfection

/
HY-K6026 In Vitro Angiogenesis Basement Membrane Matrix (Ready-to-Use)

MCE In Vitro Angiogenesis Basement Membrane Matrix (Ready-to-Use) is formulated in high-glucose DMEM and contains 50 μg/mL gentamicin. With an optimized formulation and working concentration, it requires no additional dilution or preparation and can be directly used for in vitro tube formation assays with HUVECs and other endothelial cells, supporting the establishment of in vitro angiogenesis models and related research.

Cell Biology 3D Cell Culture Basement Membrane Matrix

/

Keywords

tumor angiogenesis | VEGF | vascular normalization | tumor immunity | immune checkpoint blockade | endothelial cells